000			01259na a2200205 4500
999			_c1515 _d1515
003			PC1515
005			20181214121829.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aBenito León, Julián _9892 _eNeurología
100			_aSánchez Ferro, Álvaro _91767 _eNeurología
245	0	4	_aThe management of orthostatic hypotension in Parkinson's disease. _h[artículo]
260			_bFrontiers in neurology, _c2013
300			_a4:64.
500			_aFormato Vancouver: Sánchez-Ferro A, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson's disease. Front Neurol. 2013 Jun 10;4:64.
501			_aPMID: 23772219
504			_aContiene 149 referencias
520			_aOrthostatic hypotension (OH) is a common and disabling symptom affecting Parkinson's disease (PD) patients. We present the effect of the different therapies commonly used to manage PD on this clinical manifestation. For this purpose, we describe the relationship between OH and the current treatments employed in PD, such as L-DOPA, dopaminergic agonists, and continuous dopaminergic stimulation therapies. Additionally, we review the therapeutic measures that could be used to ameliorate OH. There are different approaches to deal with this manifestation, including pharmacological and non-pharmacological treatments, although none of them is specifically aimed for treating OH in PD.
710			_9267 _aServicio de Neurología-Neurofisiología
856			_uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677136/ _yAcceso libre
942			_n0 _2ddc _cART